Fly Intel: Top five analyst downgrades

Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Petrobras (PBR) downgraded to Neutral from Buy at Goldman Sachs with analyst Bruno Amorim saying Petrobras is in the final stages of a multi-year turnaround, but recent comments from the government on the fuels pricing policy and the appointment of a new CEO "add uncertainty on the future focus of the company." 2. T. Rowe Price (TROW) downgraded to Sell from Neutral at Citi with analyst William Katz saying the "flow story remains disappointing" with "mixed" lead indicators. 3. Novocure (NVCR) downgraded to Underperform from Neutral at Wedbush with analyst David Nierengarten noting that the data monitoring committee for Novocure's LUNAR study of TTFields in second-line non-small cell lung cancer patients recommended that the company reduce both enrollment to 276 patients from 534 and follow up time to 12 months from 18 months after a study review. 4. Synchrony (SYF) downgraded to Perform from Outperform at Oppenheimer with analyst Dominick Gabriele saying he believes stock price outperformance versus the S&P 500 since mid-2020 reflects strong cyclical rebound expectations, and continued outperformance seems limited. 5. Middlesex Water (MSEX) downgraded to Neutral from Buy at Janney Montgomery Scott with analyst Michael Gaugler citing valuation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.